Privacy Policy

Login

Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Lördag 17 Oktober | 13:41:16 Europe / Stockholm

Svenska | English

Carlsquare

Bifogade filer

Första intrycket Elicera Therapeutics, kv3 2025: CARMA-studien fortskrider, uppdatering om ELC-100 väntar

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Första intrycket Elicera Therapeutics, kv3 2025: CARMA-studien fortskrider, uppdatering om ELC-100 väntar

2025-11-14 11:55:00

Carlsquare Equity Research har publicerat en kommentar till rapporten för kv3 2025.

Läs hela kommentaren här.

Om Carlsquare

Carlsquare is a global research firm and financial advisor focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 170 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience in the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more

www.carlsquare.com